Cardiac Channelopathies

Cardiac channelopathies are a group of inherited disorders caused by mutations in genes encoding ion channel proteins or their regulatory subunits, resulting in abnormal cardiac electrical activity and a predisposition to life-threatening ventricular arrhythmias. These conditions affect structurally normal hearts — standard echocardiography and cardiac MRI are typically unremarkable — making the ECG, genetic testing, and clinical history the primary diagnostic tools. Collectively, channelopathies account for a significant proportion of sudden cardiac death (SCD) in young individuals, particularly those under 35 years of age.

The major inherited arrhythmia syndromes include Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Short QT Syndrome (SQTS), and Early Repolarization Syndrome (ERS). LQTS and Brugada Syndrome are covered in dedicated pages within this library. This page focuses on the remaining three major channelopathies: CPVT, SQTS, and ERS.

Genetic testing plays a central but nuanced role in channelopathy evaluation. Current guidelines recommend targeted genetic testing when clinical suspicion is established based on ECG findings, clinical presentation, and family history. A positive genetic result confirms the diagnosis, enables cascade family screening, and may inform prognosis and therapy (e.g., genotype-specific beta-blocker selection in LQTS). However, a negative genetic test does not exclude the diagnosis — yield varies considerably by condition (approximately 75% in LQTS type 1–3, 60% in CPVT, 20–25% in BrS, and <25% in SQTS and ERS). Variants of uncertain significance (VUS) remain a major challenge, requiring careful interpretation and longitudinal reclassification.

Family screening is essential once a channelopathy is identified. First-degree relatives should undergo clinical evaluation with ECG, and if the proband has a pathogenic variant, cascade genetic testing is recommended. Affected family members may be asymptomatic but still harbor a potentially lethal genetic substrate. Screening protocols vary by condition — exercise stress testing is critical for CPVT screening, while serial resting ECGs and provocation testing may be appropriate for Brugada and LQTS.

Overlap syndromes are increasingly recognized, where a single genetic mutation or a combination of variants produces features of more than one channelopathy. Examples include SCN5A mutations causing overlapping Brugada, LQTS type 3, and progressive cardiac conduction disease; KCNJ2 mutations producing Andersen-Tawil syndrome with features of both LQTS and CPVT-like bidirectional VT; and CACNA1C mutations linked to both Brugada and SQTS phenotypes. These overlaps underscore the concept of a continuous spectrum of ion channel disease rather than discrete entities.

In cases of autopsy-negative sudden unexplained death (SUD), molecular autopsy — post-mortem genetic testing of stored blood or tissue samples — identifies a likely causative variant in approximately 25–35% of cases. This approach is endorsed by guidelines and is critical for enabling family screening and potentially preventing further deaths within a family. The most commonly implicated genes in molecular autopsy studies are those associated with LQTS, CPVT, and Brugada Syndrome.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly lethal inherited arrhythmia syndrome characterized by adrenergically mediated polymorphic or bidirectional ventricular tachycardia in the absence of structural heart disease or QT prolongation. It is one of the most dangerous channelopathies, with an estimated mortality rate of 30–50% by age 40 in untreated individuals. The prevalence is estimated at 1:10,000.

The genetic basis of CPVT involves mutations in genes regulating intracellular calcium handling. CPVT type 1 (autosomal dominant) is caused by gain-of-function mutations in the RYR2 gene, encoding the cardiac ryanodine receptor 2 — the primary calcium release channel on the sarcoplasmic reticulum (SR). RYR2 mutations account for approximately 60% of genetically identified cases. CPVT type 2 (autosomal recessive) is caused by loss-of-function mutations in CASQ2, encoding calsequestrin 2, the major calcium-buffering protein within the SR lumen. CASQ2 mutations account for approximately 3–5% of cases. Additional rare genetic forms involve TRDN (triadin), CALM1/2/3 (calmodulin), and TECRL.

The fundamental mechanism involves diastolic calcium leak from the sarcoplasmic reticulum. During adrenergic stimulation (exercise, emotional stress), increased cAMP and protein kinase A (PKA) activity phosphorylate the RYR2 channel, further destabilizing an already abnormal channel. This produces spontaneous calcium release events during diastole, which activate the sodium-calcium exchanger (NCX) in forward mode, generating a transient inward current (I_ti) that produces delayed afterdepolarizations (DADs). When DADs reach threshold, they trigger premature ventricular complexes and, ultimately, sustained ventricular tachycardia. The key distinction from LQTS is that CPVT arrhythmias arise from triggered activity via DADs (not early afterdepolarizations), and the resting ECG is entirely normal.

The classic presentation is syncope or sudden cardiac arrest triggered by exercise or emotional stress in a child or young adult (typical onset age 7–12 years). The resting ECG is completely normal — there is no QT prolongation, no Brugada pattern, and no pre-excitation. Resting heart rate may be relatively low (sinus bradycardia). A history of exertional syncope in a young patient with a normal resting ECG and normal cardiac structure should always prompt consideration of CPVT.

The exercise stress test is the cornerstone of diagnosis. With increasing workload and catecholamine levels, a reproducible sequence of arrhythmias emerges: isolated premature ventricular complexes (PVCs) typically appear at a heart rate of 100–120 bpm, progressing to ventricular couplets, then salvos. The hallmark arrhythmia is bidirectional ventricular tachycardia — a beat-to-beat alternation of the QRS axis, typically with a right bundle branch block morphology alternating between left superior and left inferior axis. This pattern is virtually pathognomonic for CPVT (the only other condition producing bidirectional VT is digitalis toxicity). With further catecholamine load, polymorphic VT and ventricular fibrillation may occur. Supraventricular arrhythmias, particularly atrial tachycardia and atrial fibrillation, are also common during exercise testing in CPVT patients.

Management

Beta-blocker therapy is the first-line treatment and is indicated for all patients with a clinical or genetic diagnosis of CPVT. Nadolol is the preferred agent due to its long half-life providing consistent 24-hour coverage and evidence suggesting superior efficacy compared to other beta-blockers. The target dose is 1–2.5 mg/kg/day. Metoprolol has been associated with breakthrough arrhythmic events and is generally considered inferior. Propranolol is an acceptable alternative. Beta-blocker compliance must be emphasized — abrupt discontinuation can trigger rebound adrenergic surges and potentially fatal arrhythmias. Exercise restriction (avoidance of competitive sports and high-intensity activities) is recommended for all CPVT patients.

Flecainide is an important adjunctive therapy, added when beta-blockers alone do not fully suppress exercise-induced arrhythmias. Flecainide has a direct inhibitory effect on RYR2 channels, reducing diastolic calcium leak independent of its sodium channel blocking properties. This dual mechanism makes it uniquely effective in CPVT. The typical dose is 100–150 mg twice daily in adults (2–4 mg/kg/day in children). Combination therapy with nadolol and flecainide suppresses exercise-induced ventricular arrhythmias in approximately 75–80% of patients who fail beta-blocker monotherapy.

ICD implantation is recommended for CPVT patients who have survived a cardiac arrest or who continue to have sustained VT despite optimal medical therapy. However, ICD management in CPVT is uniquely challenging. ICD shocks deliver a powerful catecholamine surge that can trigger further arrhythmias, creating a potentially lethal cycle of electrical storm — shock — catecholamine surge — worsening arrhythmia — additional shocks. Programming strategies must minimize inappropriate and appropriate shocks: long detection intervals, high rate cutoffs, antitachycardia pacing (ATP) as first-line therapy, and avoidance of low-rate VT detection zones. Despite these challenges, ICDs remain life-saving for high-risk patients when combined with optimal beta-blocker and flecainide therapy.

Left cardiac sympathetic denervation (LCSD) is a surgical option for patients with recurrent arrhythmias despite maximal medical therapy or those intolerant of or non-compliant with medications. The procedure involves resection of the lower half of the left stellate ganglion and the T2–T4 thoracic sympathetic ganglia via a thoracoscopic approach. LCSD reduces norepinephrine release at the cardiac level, raising the threshold for catecholamine-triggered arrhythmias. It does not eliminate the need for beta-blocker therapy but serves as an important adjunctive measure.

Short QT Syndrome is the rarest of the major cardiac channelopathies, with fewer than 200 cases reported worldwide since its initial description by Gussak et al. in 2000. Despite its rarity, SQTS carries a high arrhythmic burden, with a significant proportion of patients presenting with sudden cardiac arrest as the first manifestation. The syndrome is characterized by abbreviated ventricular repolarization, abbreviated refractoriness, and a propensity for both atrial fibrillation and ventricular fibrillation.

SQTS is caused by gain-of-function mutations in potassium channel genes that accelerate repolarization, or loss-of-function mutations in calcium channel genes that reduce inward depolarizing current during the plateau phase. Three primary genetic subtypes have been identified based on the affected potassium channel:

SQT1 involves gain-of-function mutations in KCNH2 (hERG), the gene encoding the rapidly activating delayed rectifier potassium current I_Kr. This is the most commonly identified genetic subtype. Enhanced I_Kr accelerates phase 3 repolarization, shortening the action potential duration and the QT interval. The N588K mutation in KCNH2 is the prototypical SQT1 variant.

SQT2 is caused by gain-of-function mutations in KCNQ1, encoding the slowly activating delayed rectifier potassium current I_Ks. Enhanced I_Ks shortens repolarization, particularly during adrenergic stimulation when I_Ks is normally augmented. Notably, loss-of-function mutations in the same gene cause LQTS type 1 — illustrating how opposite functional effects on the same channel produce diametrically opposed phenotypes.

SQT3 involves gain-of-function mutations in KCNJ2, encoding the inward rectifier potassium current I_K1. Enhanced I_K1 accelerates terminal repolarization and stabilizes the resting membrane potential at more negative values, shortening the action potential and the QT interval. Additional subtypes involve loss-of-function mutations in CACNA1C (SQT4) and CACNB2 (SQT5), which reduce I_Ca,L and overlap with Brugada phenotypes.

Diagnosis

The diagnostic criteria for SQTS rely primarily on the QTc interval. A QTc <340 ms is considered diagnostic of SQTS. A QTc of 330–360 ms represents an intermediate or borderline zone that requires additional clinical context for diagnosis. It is important to note that the QT interval in SQTS shows poor rate adaptation — the QT does not lengthen appropriately at slower heart rates, which can be a useful diagnostic clue.

The ECG hallmarks include: (1) short QT interval with a QTc consistently <360 ms; (2) tall, peaked, symmetrical T waves, particularly in the precordial leads, reflecting the abbreviated repolarization and steep phase 3 of the action potential; (3) short or absent ST segment — the T wave begins almost immediately after the QRS complex; and (4) a short interval from the J-point to the T-wave peak with a normal or near-normal T-wave to QRS-end interval, reflecting preferential shortening of the action potential plateau.

The Gollob diagnostic score provides a structured approach to SQTS diagnosis, analogous to the Schwartz score for LQTS. Points are assigned across four domains: QTc interval (QTc <370 ms = 1 point, <350 ms = 2 points, <330 ms = 3 points), clinical history (cardiac arrest = 2 points, documented polymorphic VT or VF = 2 points, unexplained syncope = 1 point, atrial fibrillation = 1 point), family history (first- or second-degree relative with SQTS = 2 points, first- or second-degree relative with SCD = 1 point, SIDS = 1 point), and genotype (identified pathogenic mutation = 2 points, VUS in a culprit gene = 1 point). A score ≥4 points indicates high probability of SQTS.

On electrophysiology study, SQTS patients demonstrate markedly shortened atrial and ventricular effective refractory periods (AERP and VERP). VERPs are typically <150 ms, and VF is easily inducible with programmed stimulation — often with a single extrastimulus. The very short refractory periods create a highly vulnerable substrate where even modest premature impulses can initiate reentrant VF. Short AERPs similarly predispose to atrial fibrillation, which occurs in up to 70% of SQTS patients and may be the presenting arrhythmia.

Management

ICD implantation is the primary therapy for SQTS patients who have survived a cardiac arrest or who are deemed high risk based on the Gollob score, family history of SCD, or inducible VF on EPS. However, ICD therapy in SQTS is complicated by the tall, peaked T waves that may be oversensed by the device and counted as ventricular events, leading to double-counting and inappropriate shocks. Careful programming with adjusted sensitivity settings, T-wave discrimination algorithms, and appropriate detection intervals is essential.

Quinidine is the most effective pharmacologic therapy for SQTS. Quinidine blocks I_Kr and I_to, effectively prolonging the QT interval and increasing ventricular refractoriness. In SQT1 (KCNH2 mutations), quinidine is particularly effective because it directly antagonizes the gain-of-function I_Kr that drives the phenotype. Quinidine has been shown to normalize the QT interval, abolish VF inducibility on EPS, and prevent arrhythmic events in clinical follow-up. It is used as adjunctive therapy alongside ICD or as primary therapy in patients who refuse or cannot receive an ICD (including pediatric patients). Other antiarrhythmic drugs, including sotalol and amiodarone, have generally been ineffective in SQTS, likely because they lack the specific I_to blocking properties of quinidine.

Early repolarization (ER) on the ECG — characterized by J-point elevation and ST-segment elevation in the inferior and/or lateral leads — was long considered a benign, normal variant found in up to 5–13% of the general population, particularly among young men and athletes. This paradigm shifted dramatically in 2008 when Haïssaguerre et al. demonstrated a significantly higher prevalence of ER in the inferior leads among survivors of idiopathic ventricular fibrillation compared to controls, establishing the concept of Early Repolarization Syndrome (ERS) as a distinct arrhythmogenic entity.

The critical distinction is between the ER pattern (the ECG finding) and ER syndrome (the clinical diagnosis). The ER pattern is defined as J-point elevation ≥1 mm (0.1 mV) in two or more contiguous inferior leads (II, III, aVF) and/or lateral leads (I, aVL, V4–V6), manifesting as either QRS slurring (a smooth transition from the QRS to the ST segment) or J-wave notching (a distinct positive deflection at the terminal QRS). The ER pattern is common and carries a very low absolute risk. ER syndrome is diagnosed only when the ER pattern is present in a patient who has experienced unexplained ventricular fibrillation, polymorphic VT, or sudden cardiac arrest — i.e., the pattern becomes a syndrome only in the presence of clinical events.

Risk Stratification

Distinguishing benign ER from malignant ER is one of the most challenging problems in clinical electrophysiology. Several ECG features have been identified that increase arrhythmic risk associated with the ER pattern:

ST-segment morphology is the most important discriminator. A horizontal or descending ST segment following the J-point elevation carries significantly higher risk compared to a rapidly ascending ST segment. The ascending pattern (concave upward, leading into the upstroke of the T wave) is the typical benign variant seen in young athletes. In contrast, a horizontal or descending ST segment after J-point elevation resembles an injury pattern and is associated with a 2–4-fold increased risk of arrhythmic death.

Lead distribution matters: ER in the inferior leads (II, III, aVF) carries higher risk than ER confined to the lateral leads. A global pattern (both inferior and lateral) carries the highest risk. ER confined exclusively to the lateral precordial leads (V4–V6) is considered lowest risk and is the pattern most commonly seen in young athletes.

Additional risk features include: (1) J-wave amplitude >2 mm (0.2 mV), which doubles arrhythmic risk compared to J-point elevation of 1–2 mm; (2) dynamic changes in J-wave amplitude, particularly augmentation immediately before VF onset; (3) notched (rather than slurred) J-wave morphology in some studies; (4) family history of sudden cardiac death at a young age; and (5) the presence of short coupling interval PVCs initiating VF episodes.

Mechanism

The arrhythmogenic mechanism of ERS mirrors aspects of the Brugada hypothesis. The epicardial transient outward potassium current (I_to) creates a transmural voltage gradient during early repolarization. In the ventricular epicardium, I_to produces a prominent phase 1 notch in the action potential, which is reflected on the surface ECG as the J wave. When I_to is disproportionately large relative to inward currents (I_Na, I_Ca,L), or when inward currents are reduced, the transmural gradient is exaggerated, producing a prominent J-point elevation. Heterogeneous loss of the action potential dome across the epicardium — similar to the Brugada mechanism — creates the substrate for phase 2 reentry, generating closely coupled PVCs that can initiate VF. This mechanistic overlap has led Antzelevitch to propose the unifying concept of "J-wave syndromes" encompassing both Brugada Syndrome and ERS as manifestations of the same pathophysiologic spectrum.

Management

For survivors of VF or sustained polymorphic VT (i.e., ERS), ICD implantation is the primary therapy (Class I indication). These patients have demonstrated a malignant substrate and are at significant risk of recurrence.

Isoproterenol (1–3 mcg/min IV infusion) is the acute treatment of choice for VF storm in ERS. By augmenting I_Ca,L and enhancing inward current during the action potential plateau, isoproterenol restores the action potential dome, reduces the transmural gradient, and suppresses phase 2 reentry. The J-point elevation and J waves diminish or resolve during isoproterenol infusion. This treatment is life-saving in the acute setting and should be initiated immediately in any ERS patient with recurrent VF.

Quinidine is the primary pharmacologic agent for long-term management of ERS. Through blockade of I_to, quinidine reduces the epicardial action potential notch, diminishes the transmural voltage gradient, and suppresses the J-wave amplitude on ECG. Quinidine has been shown to reduce VF recurrence and suppress VF inducibility on EPS in ERS patients. The typical dose is 300–600 mg twice daily. Other I_to blockers have been investigated but quinidine remains the best-studied and most effective option.

For asymptomatic individuals with an ER pattern, no treatment is required. The absolute risk of a malignant arrhythmic event in an individual with the ER pattern but no clinical events is extremely low (estimated at 0.01–0.03% per year). Mass screening or prophylactic intervention is not justified. However, first-degree relatives of ERS patients should undergo ECG screening, and those with high-risk ER features should be counseled regarding warning symptoms.